Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > What's COT worth if it works....

<< Previous

Bullboard Posts

Next >>

Comment by patatsrqon Aug 08, 2019 4:48pm

227 Views

Post# 30008489

RE:What's COT worth if it works....

IMO sellers have sold, the rest like us are waiting for clinical results, then this is going to the moon with institutional & new buyers. Like it should have 5 years ago.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland